Sculptra continues to correct cheek wrinkles up to 1 year
Click Here to Manage Email Alerts
Key takeaways:
- At month 7, 66.2% of Sculptra-treated patients saw improvement vs. 38.6% of the no-treatment cohort.
- These results were maintained through month 9 (70.6%) and month 12 (71.6%).
Injectable Sculptra poly-L-lactic acid treatments significantly reduced the appearance of moderate to severe cheek wrinkles, according to a study.
Approved in April 2023 for the correction of cheek wrinkles, Sculptra poly-L-lactic acid injectable implant (PLLA-SCA; Galderma) is a plant-derived alpha-hydroxy-acid polymer that “gradually stimulates collagen formation, over the course of several treatments, to provide semi-permanent correction of facial volume loss associated with aging,” Sabrina Fabi, MD, FAAD, FAACS, of Cosmetic Laser Dermatology in San Diego, and colleagues wrote.
Fabi and colleagues conducted a randomized, evaluator-blinded study to evaluate the safety and efficacy of PLLA-SCA among immune-competent adults compared with a no-treatment control.
Patients aged older than 21 years with moderate to severe cheek wrinkles were randomly assigned 2:1 to receive a 150 mg injection of PLLA-SCA (8 mL reconstitution in sterile water for injection) immediately followed by 1 mL of lidocaine hydrochloride 2% injection or no treatment.
Ninety-seven patients received a mean 15.29 mL injection on day 1 of the study. Following this initial injection, some patients required additional treatments: 95 patients received a mean 15.26 mL injection in month 1, 86 a mean 15.1 mL injection in month 2 and 67 a mean 15.17 mL injection in month 3.
According to the Galderma Cheek Wrinkle Scale (GCWS), a higher proportion of patients treated with PLLA-SCA saw improvement of their cheek wrinkles at a resting state compared with those that did not receive treatment.
At month 7, 66.2% of PLLA-SCA-treated patients saw improvement vs. 38.6% of the no-treatment cohort (P = .0043). At the month 9 and 12 follow-ups, the proportion of patients that saw improvement increased to 70.6% and 71.6%, respectively, compared with 31.1% and 26.1% in the no-treatment group (P < .0001 for both).
The blinded-investigators also reported improvements in skin radiance, skin tightening and jawline contour in more than 95%, 88% and 85% of PLLA-treated patients, respectively.
While no patients reported serious adverse events, 20 patients did experience treatment-related/injection procedure-related adverse events, three of which were moderate in severity. Most patients also experienced post-treatment tenderness (93.5%), bruising (93.5%), swelling (87.1%) and pain (83.9%).
“Injectable PLLA-SCA treatments, administered using an immediate injection protocol, were well tolerated and provided significant reductions in the severity of moderate or severe cheek wrinkles,” the authors concluded.
Collapse
Read more about
Click Here to Manage Email Alerts